MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.82% | 19.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.83% | -4.23% | |||
| Operating Income | -27.83% | 4.23% | |||
| Income Before Tax | -38.48% | 12.83% | |||
| Income Tax Expenses | -37.91% | 272.26% | |||
| Earnings from Continuing Operations | -38.20% | 12.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 35.12% | -22.27% | |||
| Net Income | -38.24% | 12.41% | |||
| EBIT | -27.83% | 4.23% | |||
| EBITDA | -27.28% | 2.43% | |||
| EPS Basic | -38.14% | 12.64% | |||
| Normalized Basic EPS | -38.48% | 12.80% | |||
| EPS Diluted | -38.14% | 12.64% | |||
| Normalized Diluted EPS | -38.48% | 12.80% | |||
| Average Basic Shares Outstanding | 0.08% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||